Insulin-Degrading Enzyme Is a Non Proteasomal Target of Carfilzomib and Affects the 20S Proteasome Inhibition by the Drug
Carfilzomib is a last generation proteasome inhibitor (PI) with proven clinical efficacy in the treatment of relapsed/refractory multiple myeloma. This drug is considered to be extremely specific in inhibiting the chymotrypsin-like activity of the 20S proteasome, encoded by the β5 subunit, overcomin...
Збережено в:
| Автори: | , , , , , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
MDPI AG
2022-02-01
|
| Серія: | Biomolecules |
| Предмети: | |
| Онлайн доступ: | https://www.mdpi.com/2218-273X/12/2/315 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|